DEF: Carisma Therapeutics Seeks Reverse Stock Split to Avoid Nasdaq Delisting and Facilitate Merger

Carisma Therapeutics Inc. is holding a special stockholder meeting on August 5, 2025, to vote on a reverse stock split aimed at regaining Nasdaq compliance and meeting conditions for its proposed merger with OrthoCellix, Inc.

Summary

• A Special Meeting of Stockholders will be held virtually on August 5, 2025, at 10:00 a.m. Eastern Time.
• Stockholders will vote on two proposals: (1) to adopt and approve an amendment to the Restated Certificate of Incorporation to effect a reverse stock split of common stock at a ratio within the range of 1-for-10 to 1-for-50, and (2) to approve a proposal to adjourn the Special Meeting if necessary to solicit further proxies for the reverse split.
• The primary purpose of the reverse stock split is to increase the per-share market price of common stock to regain compliance with Nasdaq Listing Rule 5550(a)(2) (Capital Market Bid Price Rule) and to meet the $4.00 per share closing bid price requirement for filing an initial listing application in connection with the contemplated merger.
• Carisma Therapeutics Inc. received multiple notices of non-compliance from Nasdaq: on October 10, 2024, for the MVLS Rule ($50.0 million minimum market value of listed securities); on April 10, 2025, for the MVPHS Rule ($15.0 million minimum market value of publicly held shares); and on January 6, 2025, for the Bid Price Rule ($1.00 minimum bid price).
• On June 10, 2025, the Nasdaq Hearings Panel granted an extension to comply with listing standards, transferring the company's listing to the Nasdaq Capital Market effective June 12, 2025.
• The extension is conditional on demonstrating a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions, completing a strategic transaction, and otherwise complying with all initial listing requirements for the Nasdaq Capital Market by October 7, 2025.
• On June 22, 2025, the company entered into a Merger Agreement with Ocugen, Inc. and OrthoCellix, Inc., with the merger's consummation subject to stockholder approval of the reverse stock split.
• As of May 31, 2025, there were 41,788,096 shares of common stock outstanding and entitled to vote.
• The closing price of the company's common stock on the Nasdaq Capital Market was $0.4064 per share on June 26, 2025.
• The reverse split will not reduce the authorized number of shares of capital stock (350,000,000 common, 5,000,000 preferred) but will decrease the number of issued and outstanding shares.
• Stockholders of record as of July 3, 2025, are entitled to vote at the Special Meeting.

Sentiment

Score: 3

Explanation: While the company is taking necessary steps to address critical Nasdaq compliance issues and pursue a strategic merger, the underlying reasons for these actions – persistent non-compliance with listing rules and a very low stock price – indicate significant operational or market challenges. The reverse split itself carries risks and is often viewed negatively by investors. The merger is a strategic move, but its success is contingent on the reverse split and other factors, introducing considerable uncertainty.

Positives

• The proposed reverse stock split is a proactive measure to regain compliance with Nasdaq listing standards, potentially preventing delisting.
• The reverse stock split is a necessary condition for the consummation of the strategic merger with OrthoCellix, Inc., which could provide new strategic direction.
• A higher stock price resulting from the reverse split may increase the marketability of the common stock, making it more attractive to institutional investors and brokerage firms.
• Increased stock price and marketability could facilitate future financings and help attract and retain employees.
• The Board of Directors unanimously approved and recommends voting FOR both the reverse split and adjournment proposals.

Negatives

• The company is currently non-compliant with multiple Nasdaq listing rules, including minimum market value of listed securities, minimum market value of publicly held shares, and minimum bid price.
• There is a risk of delisting from Nasdaq if compliance is not regained by the October 7, 2025, deadline, which could reduce visibility, liquidity, and value of the common stock.
• Reverse stock splits often carry a negative perception among investors and may not guarantee a sustained increase in stock price.
• The stock price of companies that have effected reverse stock splits has sometimes declined significantly afterward.
• A reduced number of outstanding shares post-split could adversely affect liquidity.
• There is no assurance that the market price per share will exceed or remain above the $1.00 Nasdaq minimum bid price or the $4.00 merger listing requirement.
• Fractional shares resulting from the reverse split will be cashed out, potentially leading to a loss of proportional ownership for some stockholders.
• The reverse split may result in some stockholders owning 'odd lots' (less than 100 shares), which can be more difficult to sell and incur higher brokerage commissions.

Risks

• The reverse stock split may not result in a sustained increase in the per share price of common stock.
• There is no assurance that the market price per share will exceed or remain in excess of the $1.00 minimum bid price required by Nasdaq for continued listing.
• There is no assurance that the market price per share will meet the $4.00 minimum closing price requirement for filing an initial listing application in connection with the contemplated Merger.
• The market price per share of common stock after the reverse split may not rise in proportion to the reduction in the number of shares outstanding.
• The reverse split may not result in a per share price that will attract brokers and investors.
• The reverse split may not increase the company's ability to attract and retain employees.
• The market price of common stock may decrease in the future, even after the reverse split.
• The liquidity of common stock may be negatively impacted by the reduced number of outstanding shares after the reverse split.
• The reverse split may result in some stockholders owning odd lots (less than 100 shares), which may be more difficult to sell and incur higher transaction costs.
• The reverse split may not increase the marketability of common stock as intended.
• Should the overall value of common stock decline after the proposed reverse split, the actual or intrinsic value of shares held by stockholders will also proportionately decrease.
• An additional effect of the reverse split would be to increase the relative amount of authorized but unissued shares, which may, under certain circumstances, be construed as having an anti-takeover effect.

Future Outlook

The company intends to file an initial listing application for the combined company on Nasdaq following the merger. The extension of time for Nasdaq compliance is subject to demonstrating a $1.00 bid price for ten consecutive trading sessions, completing a strategic transaction, and otherwise complying with initial listing requirements for the Nasdaq Capital Market by October 7, 2025.

Management Comments

• "We believe that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world."
• "Our Board recommends that you vote: FOR the adoption and approval of the Reverse Split Proposal (Proposal 1); and FOR the approval of the Adjournment Proposal (Proposal 2)."
• "We believe enabling the Board to fix the specific ratio will provide us with the flexibility to implement the Reverse Split in a manner designed to maximize the anticipated benefits to us and our stockholders."
• "In approving and recommending the Reverse Split, our Board determined that any potential negative factors are outweighed by the potential benefits of the Reverse Split."
• "We believe that effecting the Reverse Split will help us avoid delisting from Nasdaq and any resulting consequences."
• "Accordingly, we believe that the Reverse Split is our best proactive option for demonstrating compliance with the Capital Market Bid Price Rule prior to October 7, 2025, which is one condition for continued listing on the Nasdaq Capital Market."
• "We believe that the low per-share market price of our common stock impairs our marketability to, and acceptance by, institutional investors and other members of the investing community."

Industry Context

This filing reflects a common challenge faced by small-cap biotechnology or pharmaceutical companies that experience significant stock price declines, leading to non-compliance with exchange listing standards. Reverse stock splits are a frequent strategy employed by such companies to artificially boost share price and maintain listing, often in conjunction with strategic transactions like mergers to recapitalize or pivot business focus. The need to meet specific bid price requirements for both continued listing and merger-related re-listing is typical in this sector, highlighting the intense pressure on these companies to maintain market access and investor confidence.

Comparison to Industry Standards

• Many small-cap biotech companies frequently face delisting risks from Nasdaq due to low share prices, a situation similar to Carisma Therapeutics.
• Reverse stock splits are a common, though often negatively perceived, tactic used by companies in the biotech sector to meet minimum bid price requirements, as seen with other companies like Sorrento Therapeutics or Athersys.
• The $1.00 minimum bid price for Nasdaq Capital Market and $4.00 for initial listing post-merger are standard Nasdaq requirements for companies of this size and type.
• The strategic merger with a non-Nasdaq entity (OrthoCellix) to potentially gain a Nasdaq listing for the combined entity is a common strategy for companies seeking to enhance their market presence or access capital markets, particularly when facing listing challenges.

Corporate Governance

Stakeholder Impact

• Shareholders: Will own fewer shares but proportional ownership interest (subject to fractional shares) should remain the same. Fractional shares will be cashed out. Potential for increased per-share price and marketability, but also risk of further price decline and reduced liquidity. Voting on significant corporate actions.
• Employees: A higher stock price "may help generate investor interest in us and help us attract and retain employees."
• Investors (Institutional/Brokerage Firms): The reverse split aims to make the stock more attractive by increasing its per-share price, potentially overcoming internal policies against investing in low-priced stocks.
• Nasdaq: Compliance with listing rules is critical for the company's continued listing on the exchange.
• OrthoCellix, Inc.: The merger is contingent on Carisma's stockholders approving the reverse stock split and other conditions, directly impacting OrthoCellix's strategic outcome.

Next Steps

• Hold a Special Meeting of Stockholders on August 5, 2025, to vote on the reverse stock split and adjournment proposals.
• If the reverse stock split is approved, the Board will determine the exact ratio (within 1-for-10 to 1-for-50) and timing, and file the amendment by December 31, 2025.
• Demonstrate compliance with Nasdaq Capital Market Bid Price Rule ($1.00 for 10 consecutive sessions) by October 7, 2025.
• Complete a strategic transaction (Merger with OrthoCellix, Inc.) by October 7, 2025.
• Otherwise demonstrate compliance with all initial listing requirements for the Nasdaq Capital Market by October 7, 2025.
• Hold a separate special meeting of stockholders to obtain approvals necessary to complete the Merger and related matters.
• File an initial listing application for the combined company to list its securities on Nasdaq.
• Publish final voting results in a current report on Form 8-K within four business days after the Special Meeting.

Key Dates

Recommendation

Keywords

Carisma Therapeutics, reverse stock split, Nasdaq delisting, Nasdaq compliance, merger, OrthoCellix, proxy statement, corporate governance, stock marketability, institutional investors, CARM